NDA 020649 · Endo Operations
Edex
Alprostadil · Injection · Prostaglandin Analog; Prostaglandin E1 Agonist
Last checked: Nov 19, 2026Latest source record: Nov 17, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Jun 12, 1997
Approved uses
1
Original approval plus efficacy supplements
Registered trials
145
40 Phase 3, 8 recruiting
FAERS reports
1,989
1,604 serious, 241 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 27, 2024.
INDICATIONS AND USAGE edex ® is indicated for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.
Mechanism: Mode of Action Alprostadil is a smooth muscle relaxant. Precontracted isolated preparations of the human corpus cavernosum, corpus spongiosum and cavernous artery are relaxed by alprostadil. Alprostadil has been shown to bind to specific receptors in human penile tissue. Two types of receptors that differ in their PGE 1 binding affinity have been identified. The binding of alprostadil to its receptors is accompanied by an increase in intracellular cAMP levels. Human cavernous smooth muscle cells respond to alprostadil by releasing intracellular calcium into the surrounding medium. Smooth...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 12, 1997 Original approval · Type 3 - New Dosage Form Review
7 products under this application
- EDEX · ALPROSTADIL 0.01MG/VIAL · INJECTABLE, INJECTION · Prescription
- EDEX · ALPROSTADIL 0.02MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- EDEX · ALPROSTADIL 0.005MG/VIAL · INJECTABLE, INJECTION · Discontinued
- EDEX · ALPROSTADIL 0.02MG/VIAL · INJECTABLE, INJECTION · Prescription
- EDEX · ALPROSTADIL 0.04MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- EDEX · ALPROSTADIL 0.01MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- EDEX · ALPROSTADIL 0.04MG/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Alprostadil" as an intervention, any sponsor and status, largest first.
- Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of LaborPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT00308711 · 1,308 participants · Start Apr 2006 · Primary completion Aug 2007
Drug: Misoprostol vaginal insert 100 mcg; Misoprostol vaginal insert 50 mcg and 1 more · For: Cervical Ripening; Labor, Induced
Sites: Birmingham, Alabama; Mesa, Arizona; Phoenix, Arizona · 52 sites in all
- Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic StrokePivotal-lookingStatus unknown
The First Hospital of Jilin UniversityAcademic, hospital or other
NCT03252626 · 950 participants (planned) · Start Apr 18, 2024 · Primary completion Dec 31, 2024
Drug: Alprostadil; Normal saline · For: Stroke
- Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic ConstipationPivotal-lookingCompleted
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT01674530 · 909 participants · Start Oct 2012 · Primary completion Jan 2014
Drug: Lubiprostone; Lubiprostone and 1 more · For: Chronic Idiopathic Constipation
Sites: Birmingham, Alabama; Dothan, Alabama; Huntsville, Alabama · 93 sites in all
- Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IVPivotal-lookingCompleted
NCT00596752 · 840 participants · Start Mar 2004 · Primary completion May 2013
Drug: Alprostadil · For: Peripheral Arterial Occlusive Disease
Sites: Pilsen, Czechia; Ústí nad Labem, Czechia; Karlsbad, Germany · 78 sites in all
- Evaluation of Clinical Equivalence Between Two Lubiprostone ProductsPivotal-lookingCompleted
Anchen Pharmaceuticals, IncIndustry
NCT01372423 · 808 participants · Start May 2011 · Primary completion Jun 2012
Drug: Lubiprostone; Placebo · For: Chronic Idiopathic Constipation
Sites: Dothan, Alabama; Huntsville, Alabama; Mobile, Alabama · 79 sites in all
- Labor Induction and Maternal BMI, Comparison of Different Pre-induction Cervical Ripening MethodsPivotal-lookingStatus unknown
Hillel Yaffe Medical CenterGovernment (non-federal)
NCT02223949 · 624 participants (planned) · Start Oct 2014 · Primary completion Oct 2016
Drug: PGE1 tablet · For: Obesity; Labor Complications
Sites: Hadera, Israel
- Lubiprostone in Children With Functional ConstipationPivotal-lookingCompleted
Sucampo Pharma Americas, LLCIndustry
NCT02042183 · 606 participants · Start Dec 13, 2013 · Primary completion Jul 27, 2016
Drug: Lubiprostone; Placebo · For: Constipation - Functional
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 117 sites in all
- ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart FailurePivotal-lookingNot yet recruiting
Biopeutics Co., LtdIndustry
NCT00610051 · 600 participants (planned) · Start Oct 2026 · Primary completion Nov 2029
Drug: Alprostadil · For: End Stage Cardiac Failure; HFrEF - Heart Failure With Reduced Ejection Fraction; NYHF Class III-IV
Sites: Vienna, Austria
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective257
- off label use128
- haemoglobin decreased82
- lymphocyte count decreased79
- diarrhoea73
- pyrexia72
- cardiac failure70
- priapism62
- blood urea increased59
- condition aggravated57
- anaemia56
- blood glucose increased56
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 49 |
| 2005 | 66 |
| 2006 | 79 |
| 2007 | 42 |
| 2008 | 57 |
| 2009 | 31 |
| 2010 | 63 |
| 2011 | 113 |
| 2012 | 76 |
| 2013 | 38 |
| 2014 | 24 |
| 2015 | 119 |
| 2016 | 144 |
| 2017 | 184 |
| 2018 | 114 |
| 2019 | 138 |
| 2020 | 108 |
| 2021 | 114 |
| 2022 | 86 |
| 2023 | 80 |
| 2024 | 102 |
| 2025 | 87 |
| 2026 | 74 |
Recalls
1 FDA enforcement reports for this application.
Feb 22, 2017 · Class II · Terminated
Lack of Assurance of Sterility: Defective container resulting in the lack of sterility assurance. ok thanks
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Erectile dysfunction.
Khera M, Goldstein I · BMJ Clin Evid 2011 · Systematic Review
- Pharmacological treatment for Buerger's disease.
Cacione DG, Macedo CR, do Carmo Novaes F, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacological treatment for Buerger's disease.
Cacione DG, Macedo CR, Baptista-Silva JC · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacological treatment for Buerger's disease.
Cacione DG, Baptista-Silva JC, Macedo CR · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Alprostadil for hypertensive nephropathy: A systematic review and meta-analysis of randomized controlled trials.
Fu H, Hou W, Zhang Y, et al. · PLoS One 2022 · Meta-Analysis, Systematic Review
- Erectile dysfunction: a global review of intracavernosal injectables.
Duncan C, Omran GJ, Teh J, et al. · World J Urol 2019 · Systematic Review
Sponsor: Endo Operations
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.